The new H1N1 diagnostic reagent, developed by the National Institute of Diagnostics and Vaccine Development in Infectious Diseases and Beijing Wantai Biomedicine Corporation with the support of MOST, was approved to be launched into the market.

The clinical tests of this new reagent, done by prestigious clinical units in China, have shown its superior sensitivity and specificity.